TrialClinical lymphoma, myeloma & leukemia2019

Phase II Study of the PD-1 Inhibitor Pembrolizumab for the Treatment of Relapsed or Refractory Mature T-cell Lymphoma.

Stefan K Barta et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.